Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Bashir, Qaiser  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Oran B, Jimenez AM, de Lima M, Popat UR, Bassett R, Andersson B, Borthakur G, Bashir Q, Chen J, Ciurea SO, et al. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015.
Santos DMCordas D, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, et al. Age is a prognostic factor for the overall survival of multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, et al. Allogeneic Transplantation after Myeloablative Rituximab/BEAM +/- Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-up Results. Biol Blood Marrow Transplant. 2019.
B
Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, et al. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to whites: a propensity-score matched analysis. Am J Hematol. 2021.
Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, et al. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv. 2020;4(19):4834-4837.
C
Greenbaum U, Kebriaei P, Srour SA, Olson A, Bashir Q, Neelapu SS, Rezvani K, Shpall EJ. Chimeric Antigen Receptor T-cell Therapy Toxicities. Br J Clin Pharmacol. 2020.
Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Im JSeon, et al. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2020:1-8.
D
Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, et al. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016.
F
Oran B, Saliba RM, Mehta RS, Alousi AM, Marin D, Valdez BC, Chen J, Bashir Q, Ciurea SO, Olson AL, et al. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2021.
H
Srour SA, Saliba RM, Bittencourt MCb, Perez JMiguel Ram, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, et al. Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation. Am J Hematol. 2019.
Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, et al. HLA Factors Versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther. 2022.
I
Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Betul O, Bashir Q, Olson A, Nieto Y, et al. Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019.
Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, A Cornelison M, Rondon G, Parmar S, Shah ND, Bashir Q, et al. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018.
L
Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, et al. Lenalidomide-Based Maintenance After Autologous Hematopoietic Stem Cell Transplant for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther. 2022.
Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, et al. Long-term outcomes of allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma. Transplant Cell Ther. 2022.
M
Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, et al. Melphalan based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. 2018.
Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, et al. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther. 2021.
N
Kongtim P, Hasan O, Perez JMiguel Ram, Varma A, Wang SA, Patel KP, Chen J, Rondon G, Srour S, Bashir Q, et al. A Novel Disease Risk Model for Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019.
O
Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJoy, Bashir Q, Rondon G, et al. Outcome of Multiple Myeloma With Chromosome 1q Gain and 1p Deletion After Autologous Hematopoietic Stem Cell Transplantation: propensity-score matched analysis: Outcome of 1q+/1p- MM pts after auto-HCT. Biol Blood Marrow Transplant. 2019.
Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, et al. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol. 2016.
P
Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Bashir Q, Qazilbash MH, Andersson BS. Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells. Exp Hematol. 2020.
Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, et al. Post-Transplantation Cyclophosphamide vs Tacrolimus and Methotrexate Graft-versus-Host Disease Prophylaxis For HLA-Matched Donor Transplantation. Transplant Cell Ther. 2022.
Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, et al. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. 2018.
Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, Oran B, Hosing C, Bashir Q, Qazilbash MH, et al. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Am J Hematol. 2022.
R
Qazilbash MH, Saini NY, Soung-Chul C, Wang Z, Stadtmauer E, Baladandayuthapani V, Lin H, Tross B, Honhar M, Rao SS, et al. A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients. Blood. 2021.

Pages